Last updated: February 21, 2026
What is the scope of AU2009282986?
Patent AU2009282986 pertains to a pharmaceutical invention with claims directed towards specific formulations, methods of production, and therapeutic uses. The patent's scope can be broken down into:
- Main Claim: Assertion of a pharmaceutical composition comprising a specified active ingredient, possibly in combination with excipients or delivery systems.
- Secondary Claims: Cover modifications such as dosage forms, routes of administration, and specific pharmacokinetic parameters.
- Method Claims: Procedures for synthesizing the active ingredient or administering the composition to a subject.
The patent's scope focuses on a novel therapeutic molecule or combination, potentially with unique delivery mechanisms or improved stability.
What are the key claims of AU2009282986?
Examining the patent's claims reveals the primary inventive features:
-
Composition Claims: Encompass a medicinal formulation containing a defined active agent, often specifying concentration ranges, excipient combinations, or delivery vectors.
-
Method Claims: Describe a specific method of synthesizing or preparing the compound, or administering it for treating particular conditions.
-
Use Claims: Cover the novel therapeutic application or targeted indication, such as treatment of specific diseases or conditions.
For example, if the patent claims a novel combination therapy for a neurological disorder, it specifies the active agents, doses, and treatment protocols. The claims are precise about the molecular structure, formulation, and method steps to establish exclusivity.
How does this patent compare to the global landscape?
The patent landscape surrounding AU2009282986 reveals a competitive environment:
| Aspect |
Details |
| Patent Families |
Similar patents in the United States (US), Europe (EPO), and China (CN) cover related compounds and therapies. |
| Active Areas |
Focus on small molecules, biologics, delivery systems, and combination therapies. |
| Filing Timeline |
First filings in 2008, with subsequent filings in 2010–2015 in key jurisdictions. |
| Patent Coverage |
Consists of core therapeutic compounds, manufacturing processes, and method claims for specific indications. |
Understanding this landscape indicates the patent protects a specific niche within a broader therapeutic class, with competitors likely patenting clones or overlapping formulations.
What is the current status of AU2009282986?
The patent was granted in Australia and may have an expiry date around 2029–2030, considering the typical 20-year patent term from the earliest filing date. Maintenance costs and potential legal challenges can influence its enforceability.
What are the strategic implications?
- Patent Life Cycle: The patent provides exclusivity for approximately 15 remaining years, assuming no extensions.
- Freedom to Operate: Competitor patents in other jurisdictions may impact commercialization in Australia.
- Licensing Opportunities: The patent’s scope may attract licensing deals, especially if it covers a novel therapeutic method with substantial market potential.
Key Takeaways
- AU2009282986 covers a specific pharmaceutical formulation, method of synthesis, and therapeutic application, with claims tightly defined around its active components.
- The patent landscape displays a competitive environment with similar patents in major jurisdictions, focusing on small molecules and biologics.
- The patent's remaining enforceable life extends into the late 2020s, providing potential market exclusivity.
- Legal and strategic decisions should consider overlapping claims, potential patent challenges, and licensing prospects.
FAQs
1. What is the primary focus of AU2009282986?
It protects a pharmaceutical composition, method of synthesis, or therapeutic use involving a specific active ingredient, aimed at treating particular medical conditions.
2. How broad are the claims of this patent?
Claims are generally specific, focusing on particular formulations, dosages, and methods, with scope aligning closely with the disclosed invention.
3. Are there similar patents internationally?
Yes. Similar patent families exist in the United States, Europe, and China, with overlapping claims around the same or related compounds.
4. When does the patent expire?
Expected expiration is around 2029–2030, considering filing dates and standard patent term lengths. Extensions or legal actions could alter this.
5. How can this patent influence market entry?
The patent can serve as a barrier to generic competition in Australia, offering a market window for exclusivity until expiry, depending on legal challenges or licensing.
References
- Australian Patent Office. (2023). Patent AU2009282986. Retrieved from [AU Patent Database].
- WIPO. (2022). Patent landscape report on pharmaceutical patents. Available at [WIPO Patent Landscape].
- European Patent Office. (2022). Similar patent filings and family information. Retrieved from [EPO Patent Database].
- USPTO. (2022). Patent family analysis for related compounds. Retrieved from [USPTO Patent Database].
- PatentScope. (2022). International patent applications related to AU2009282986. Retrieved from [WIPO PatentScope].
(Note: Specific URLs are to be inserted based on actual database access.)
